Characteristics of anti-hepatitis C virus antibody-positive patients in a hospital setting in Douala, Cameroon  by Luma, Henry Namme et al.
International Journal of Infectious Diseases 45 (2016) 53–58Characteristics of anti-hepatitis C virus antibody-positive patients
in a hospital setting in Douala, Cameroon
Henry Namme Luma a,b,*, Servais Albert Fiacre Bagnaka Eloumou a,c, Agnes Malongue a,
Elvis Temfack a,d, Dominique Noah Noah b, Olivier Donfack-Sontsa e, Ivo Che Ditah f
aDouala General Hospital, PO Box 4856, Douala, Cameroon
b Faculty of Medicine and Biomedical Sciences, University of Yaounde´ I, Yaounde´, Cameroon
c Faculty of Medicine and Pharmaceutical Sciences, University of Douala, Douala, Cameroon
d Paris Descartes University, Paris, France
e London School of Hygiene and Tropical Medicine, University of London, London, UK
fMedical College of Wisconsin, Milwaukee, Wisconsin, USA
A R T I C L E I N F O
Article history:
Received 11 December 2015
Received in revised form 1 February 2016
Accepted 17 February 2016
Corresponding Editor: Eskild Petersen,
Aarhus, Denmark.
Keywords:
Hepatitis C virus
Clinical
Virological
Histological
Genotype
S U M M A R Y
Introduction: Hepatitis C virus (HCV) infection is a major public health problem, especially in resource-
limited settings where many patients are diagnosed at the stage of complications. In Cameroon, where
HCV is endemic, little is known about the clinical, biological, and virological proﬁle of HCV-infected
patients.
Methods: A clinical case note review of all patients positive for antibodies against HCV diagnosed at the
gastroenterology outpatient clinic of the Douala General Hospital, Cameroon, from January 2008 to
December 2014, was performed.
Results: A total of 524 patients were included in the study, 53% of whom were female. The mean age was
56  13 years. A history of blood transfusion and a history of scariﬁcation were the most common potential
risk factors for HCV exposure, as found in 16% and 13% of the study population, respectively. Current alcohol
use was found in 24% of patients. Co-infection with hepatitis B virus and HIV was 3.6% and 3.4%, respectively.
Among the patients, 39% had no complaint at diagnosis; only 16% were diagnosed through a routine medical
checkup. Clinically, the most common ﬁnding was hepatomegaly (26.1% of patients). Transaminases above
the upper limit of normal were found in 55.2% of patients, particularly those aged >57 years (p = 0.001).
Genotypes 1 (43.95%), 2 (25.11%), and 4 (28.25%) were the most common. Liver cirrhosis was present in 11%
of patients and hepatocellular carcinoma in 4%, the latter being more common in males (p < 0.001) and in
those aged >57 years (p = 0.03).
Conclusions: In the gastroenterology clinic of Douala General Hospital, while almost 40% of patients who
were anti-HCV antibody-positive were asymptomatic and diagnosed fortuitously, some already
presented complications, including cirrhosis and hepatocellular carcinoma. There is an urgent need to
put in place programs to increase awareness and diagnosis of HCV infection and to develop extensive and
targeted anti-HCV treatment guidelines to improve the management of these patients in Cameroon.
 2016 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
Contents lists available at ScienceDirect
International Journal of Infectious Diseases
jou r nal h o mep ag e: w ww .e lsev ier . co m / loc ate / i j id1. Introduction
Hepatitis C virus (HCV) infection is a major public health
problem.1 Globally about 185 million people are chronically
infected, 90% of whom are in low and middle income countries,2–
5 resulting in substantial morbidity and mortality.6 HCV infection* Corresponding author. Fax: +237 243370146.
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license (http://creativecommons.org/licenses/by-nc-nd/4.0/).often remains asymptomatic and unrecognized until complications
arise, and for many who have been diagnosed, treatment remains
unavailable.7 HCV can induce hepatic inﬂammation, which may
result in progressive ﬁbrosis leading to cirrhosis and hepatocellular
carcinoma (HCC).8,9 Standardized mortality ratios for liver-related
death are 16- to 46-fold higher in infected individuals than in the
general population.6,10,11 In Cameroon, the prevalence of anti-HCV
antibody positivity is estimated to be about 13%.12
The societal, clinical, and economic burdens imposed by
untreated HCV are expected to continue to soar in coming yearsciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
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burden and low access to HCV services emphasizes the urgent
need for resource-limited settings to be included in the global
HCV agenda. As such, programs aimed at improving awareness
and reducing disease progression and transmission need urgent
scale-up without further delay. Consequently, epidemiological
studies to improve the understanding of disease burden and
HCV service provision and uptake are indispensable if the global
control of HCV infection is to be achieved.14 However, data on
access to HCV diagnostic and treatment services in resource-
limited settings are very scarce.14 Population-based studies on
HCV prevalence, molecular epidemiology, and clinical and
laboratory characteristics have been performed only in a few
African countries, and most of these have been based on small
groups of individuals.15
Although it is irrefutable that extensive assessments are mostly
limited to patients who are subsequently treated, thus reﬂecting an
attempt to conserve limited health resources, hope is not lost that
antiviral treatment will increasingly be offered in resource-limited
settings through government and donor agency interventions,
particularly to those with severe liver disease.16 Paradoxically, in a
region with a high disease burden, published data on disease
characteristics still remain very scarce,17 although such data are of
great importance in improving our understanding of the disease
and in targeting patient treatment, especially in resource-limited
settings aspiring to improve HCV treatment. Thus the present
study was performed to describe the epidemiological, clinical,
biochemical, virological, and histological characteristics of anti-
HCV antibody-positive patients attending the gastroenterology
outpatient clinic of Douala General Hospital (DGH), with the aim of
improving our understanding of HCV infection in Cameroon, in
order to have a template on which to create an HCV treatment
clinic in this hospital.
2. Methods
2.1. Study design and setting
This descriptive cross-sectional study was carried out in DGH, a
tertiary health facility in Douala, the largest city and economic
capital of Cameroon, with an estimated population of over three
million inhabitants. This hospital has a capacity of 320 beds and
hosts many services and units, among which is a gastroenterology
unit to which most patients with liver diseases are referred. It also
has a fully functional laboratory (subject to periodic quality control
and validation) where most baseline tests relevant to HCV
diagnosis and management are done.
2.2. Data collection and laboratory analysis
The study was approved by the DGH Ethics Committee for
Research. A thorough clinical case note review was performed. All
patients tested and declared positive for anti-HCV antibody at the
gastroenterology outpatient clinic between January 2008 and
December 2014 were included. Information obtained from the ﬁles
included socio-demographic characteristics (age, sex, marital
status, profession, place of residence), circumstances of HCV
diagnosis, potential risk factors (blood transfusion, scariﬁcation,
piercing, tattoo, surgery, family history of liver disease or cancer),
comorbidities (diabetes mellitus, hypertension, current alcohol
use and smoking), insurance, symptoms and signs associated with
HCV infection (pedal edema, ascites, splenomegaly, hepatomegaly,
jaundice), and laboratory test results (alanine aminotransferase
(ALT), aspartate aminotransferase (AST), serum albumin, full blood
count, hepatitis B surface antigen (HBsAg), and anti-HIV serology).At DGH, anti-HCV testing is done ﬁrst using a rapid test on
plasma, the DiaSpot HCV Test Strip (DiaSpot Diagnostics, USA). For
those who are positive, conﬁrmation is carried out using a third-
generation solid-phase ELISA (Recombi LISA HCV Antibody Test,
Ref. E0511; CTK Biotech, San Diego, CA, USA) following the
manufacturer’s instructions. This test, which qualitatively detects
IgG and IgM for HCV, is highly sensitive and speciﬁc (100%), as
indicated in the manufacturer’s manual. Following anti-HCV
positive testing, further evaluation is proposed to those who can
afford it, including HCV RNA quantiﬁcation, HCV genotyping, and
the assessment of liver ﬁbrosis with the FibroTest (BioPredictive,
Paris, France) and HCV activity using ActiTest (BioPredictive). HCV
RNA quantiﬁcation and genotyping are done by real-time PCR (RT-
PCR). These tests are not performed routinely in Cameroon. Thus,
blood samples from HCV-positive patients are collected in
ethylenediaminetetraacetic acid (EDTA) tubes, as speciﬁed by
the respective test procedures, separated, frozen, and packaged in
temperature-controlled thermochip containers and transported to
an accredited laboratory in Paris, France where they are analyzed;
the results are reported within 10 days either by fax or by e-mail.
Hepatitis B virus (HBV) was detected using a one-step HBsAg
test strip (DiaSpot HBsAg; DiaSpot Diagnostics), which if positive
was conﬁrmed with an HBsAg ELISA test (BIOREX; Biorex
Diagnostics Limited, Antrim, UK).
HIV diagnosis was done using a positive rapid test (Determine
HIV 1/2; Alere Medical Co., Chiba, Japan) and conﬁrmed according
to the Cameroon National AIDS Control Program guidelines by
antibody detection in two successive samples using a third-
generation ELISA test (BIOREX; Biorex Diagnostics Limited).
The diagnosis of liver cirrhosis and HCC were done mainly
through clinical, laboratory, and radiological assessments by the
resident gastroenterologists; these were recorded in the ﬁles.
Participants described as ‘insured’ were those who had full or
partial compensation for medical expenses. ‘Alcohol use’ was
reserved for those who admitted to drinking alcohol by a simple
‘yes’ to the question ‘‘Do you drink alcohol?’’ A ‘routine checkup’
was a scheduled health checkup appointment with a doctor that
involved a physical examination and appropriate screening tests
for speciﬁc diseases with the aim of monitoring health as well as
assisting in the prevention and early detection of disease.
‘Systematic screening’, on the other hand, was reserved for mass
screening of speciﬁc population groups, symptomatic or not, for
the presence of anti-HCV antibodies. The METAVIR score, which is
a conversion from the FibroTest/ActiTest results, was used to
categorize ﬁbrosis in chronic hepatitis C according to a 5-stage
classiﬁcation: F0 (no ﬁbrosis), F1 (portal and periportal ﬁbrosis
without septa), F2 (portal and periportal ﬁbrosis with rare septa),
F3 (numerous septa without cirrhosis), and F4 (cirrhosis). The
METAVIR score also categorized activity according to a 4-grade
classiﬁcation: A0 (no activity), A1 (minimal activity), A2 (moderate
activity), and A3 (severe activity).
2.3. Statistical analysis
Data were entered into Epidata version 3.1 software and
exported for analysis into Stata version 12.0 statistical software
(Stata Corp., College Station, TX, USA). Categorical variables were
presented as counts and their percentages. Continuous variables
were presented as the mean (with the standard deviation (SD)) or
median (with the interquartile range (IQR)) where appropriate, or
as counts and percentages after categorizing using predeﬁned cut-
offs or the median. Comparisons of different variables were done
by sex and age (categorized by median age) using Pearson’s Chi-
square test or Fisher’s exact test and the Student t-test or the
Wilcoxon rank sum test, where appropriate; the reported p-value
was considered signiﬁcant if it was less than 0.05.
Table 1
General characteristics of the study population
Variables Number Count (percentage)
Age in years 524
< 20 3 (0.57)
20–39 51 (9.9)
40-59 262 (59.8)
60 208 (39.6)
Male gender 524 245 (47)
Marital status 524
In couple (married/cohabitating) 369 (70)
Alone (single/divorced/widowed) 155 (30)
Profession 524
Employed 281 (54)
Unemployed 243 (46)
Residence 524
Urban 398 (76)
Rural 126 (24)
Insured 524 53 (10)
Diagnosis circumstances 524
Asthenia 19 (4)
Jaundice 6 (1)
Routine check up 79 (16)
Fever 19 (4)
Blood donation 9 (2)
Systematic screening 17 (3)
Unknown 150 (29)
Others 225 (44)
Clinical Findings 524
Joint Pains 45 (9)
Ankle Oedema 45 (9)
Hepatomegaly 137 (26)
Splenomegaly 44 (8)
Results are presented as count (percentage) or otherwise stated
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A total of 524 clinical case ﬁles of anti-HCV antibody-positive
patients were examined.
3.1. Socio-demographic characteristics of the study participants
The mean age of the study population was 56 (SD 13) years; 90%
were above the age of 40 years. Female sex was predominant (53%),
although this was not statistically signiﬁcant. Most of the patients
were of urban origin (76%) and more than 90% of the study
population had no health insurance coverage. Only 16% of the study
population had been diagnosed at a routine checkup (Table 1).
3.2. Potential risk factors, comorbidity, and co-infection
A potential risk factor for acquiring HCV infection was identiﬁed
in 37.9% (199/524) of participants. The most frequent were a
history of surgery, history of blood transfusion, and history of
scariﬁcation (18%, 16%, and 13% of the study population,
respectively). A history of blood transfusion and scariﬁcation
were signiﬁcantly more common in females than males (p < 0.05)
(Table 2). Blood transfusion was also a factor strongly associated
with HCV acquisition in those who were aged 57 years
(p = 0.008). Among the patients studied, 3.6% (n = 19) were co-
infected with HBV and 3.4% (n = 18) were co-infected with HIV.
Diabetes and hypertension were common, present in 18% (n = 95)
and 39% (n = 204) of patients, respectively (Table 2).
3.3. Clinical and laboratory characteristics
In 39% of patients conﬁrmed to be anti-HCV positive, there was
no suggestive presenting complaint. The most common physical
sign was a hepatomegaly, present in 26.1% of patients, predomi-
nantly found in men (p = 0.017). Presumed symptoms of extra
hepatic HCV manifestation (joint pains) was found in 9% of patients
(Table 1). Transaminases above the upper limit of normal were
found in 55% of patients (Table 3). HCV genotype and viral load
results were available for 43.5% (228) and 42.2% (221) patients
respectively, of which 19 subtypes were identiﬁed. The most
common genotype was type 1 in 43.4% of patients. Men were more
likely to have a higher median viral load for HCV non-genotype
2 than women (Table 3). The male sex and advanced age were
factors signiﬁcantly associated with advanced ﬁbrosis-Metavir
F3 F4 (p < 0.05). Liver cirrhosis and hepatocellular carcinoma
(HCC) were more signiﬁcantly common in those aged above
57 year (p < 0.05) and men were more likely to develop HCC than
women (p < 0.001) (Table 4).Table 2
History of potential risk factors and associated comorbidities in 524 anti-HCV-positive
Risk factors and comorbidities Female Male p
Risk factors
History of blood transfusion 58 (21) 27 (11) 
History of scariﬁcation 43 (16) 23 (9) 
History of piercings 1 (0.36) 0 (0) 
History of tattoo 0 (0) 2 (0.82) 
History of jaundice 26 (9) 9 (4) 
History of surgery 55 (20) 37 (15) 
History of ascites 10 (4) 3 (1) 
History of liver cancer in the family 8 (3) 5 (2) 
Family history of viral hepatitis 10 (4) 8 (3) 
Comorbidities
Diabetes 48 (17) 47 (19) 
Hypertension 106 (38) 98 (40) 
Current alcohol use 39 (14) 85 (35) <
Current cigarette smoking 6 (2) 26 (11) <
a Chi-square test or Fisher’s exact test.4. Discussion
The natural history, epidemiology, diagnosis, and therapy of
HCV are the object of continuing research.18,19 The present study
highlights the epidemiological, clinical, and laboratory character-
istics of patients with a positive HCV antibody serology in a region
known to have a high prevalence of HCV disease but with little
published clinical and laboratory data. The full magnitude of the
burden of HCV-related chronic liver disease may not be realized, as
most patients are asymptomatic or are evaluated only when
complications occur.20,21
A main ﬁnding of this study was that 90% of the patients were
over the age of 40 years. A past history of surgery, blood
transfusion, and scariﬁcation were the most prominent potential
risk factors. Hypertension and diabetes mellitus were the most
common comorbid factors, present in 39% and 18.2%, respectively.
Alcohol use was 23.8%. Co-infection with HIV and HBV were low in patients, compared by sex and median age
-Valuea 57 years >57 years p-Valuea Total (%)
0.002 55 (20) 30 (12) 0.008 85 (16)
0.035 38 (14) 28 (11) 0.31 66 (13)
- 1 (0.37) 0 (0) - 1 (0.2)
- 1 (0.37) 1 (0.40) - 2 (0.4)
0.01 16 (6) 19 (8) 0.47 35 (7)
0.17 43 (16) 49 (19) 0.31 92 (18)
0.083 0 (0) 13 (5) - 13 (2)
0.55 7 (3) 6 (2) 0.86 13 (2)
0.86 9 (3) 9 (4) 0.89 18 (3)
0.55 36 (13) 59 (24) 0.003 95 (18)
0.66 70 (26) 134 (53) <0.0001 204 (39)
0.0001 75 (28) 49 (20) 0.027 124 (24)
0.0001 25 (9) 7 (3) 0.002 32 (6)
Table 3
General laboratory characteristics of the study population
Parameter Number n (%)
AST 447
Normal (<40 IU/l) 201 (44.9)
Above the upper limit of normal 246 (55.1)
ALT 444
Normal (<40 IU/l) 199 (44.8)
Above the upper limit of normal 246 (55.2)
Hemoglobin 426
<12 g/dl 146 (34.3)
12 g/dl 280 (65.7)
Platelets 415
<100  109/l 62 (14.9)
100  109/l 353 (85.1)
Albuminemia (normal >35g/l) 170
<35 g/l 71 (41.8)
35 g/l 99 (58.2)
Bilirubin (normal <11 U/l) 109
<11 U/l 75 (68.8)
11 U/l 34 (31.2)
HCV genotype 228
G1 99 (43.4)
G2 56 (24.6)
G4 67 (29.4)
Mixed (1 + 4; 2 + 4; 4 + 5; 1,4 + 5) 6 (2.6)
Viral load by genotype 221
<6  105 copies/ml G2
<8  105 copies/ml non-G2
118 (53.4)
6  105 copies/ml G2
8  105 copies/ml non-G2
103 (46.6)
AST, aspartate aminotransferase; ALT, alanine aminotransferase.
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39% did not have a presenting complaint, and a medical checkup
was the most common diagnostic circumstance. On clinical
examination, hepatomegaly and splenomegaly were present in
26.1% and 8.4% of the population, respectively, and presumed
extra-hepatic manifestations of HCV were present in 9% ofTable 4
Clinical biochemical, virological, and histological characteristics, stratiﬁed by sex and m
Parameters Female Male p-Va
Clinical
Hepatomegaly 61 (45) 76 (55) 0.0
Joint pains 24 (53) 21 (47) 0.9
Jaundice 3 (43) 4 (57) 0.7
Lower limb edema 21 (47) 24 (53) 0.4
Splenomegaly 23 (52) 21 (48) 0.8
Cirrhosis 32 (56) 25 (44) 0.6
Hepatocellular carcinoma 3 (14) 18 (86) <0.0
Laboratory
Hemoglobin, median (IQR), g/dl 12.4 (11.1–13.3) 13.4 (11.5–14.6) <0.0
Platelets, median (IQR), 109/l 198 (140–243) 170 (128–222) 0.0
AST, median (IQR), IU/l 42 (27–74) 46 (31–78) 0.1
ALT, median (IQR), IU/l 40 (27–66) 46 (32–78) 0.0
Bilirubin, median (IQR), U/l 7 (4.1–12.3) 9.9 (5.8–15.1) 0.1
Albuminemia, median (IQR), g/l 36 (29.5–42) 36.1 (31.6–43) 0.4
Viral load, 105
Genotype 1 3.4 (1.2–16.9) 7.2 (2.0–19.7) 0.2
Genotype 2 18.1 (3.9–28.1) 8.3 (2.9–48.9) 0.7
Genotype 4 5.5 (3.6–13.0) 10.7 (4.8–28.2) 0.1
Fibrosis score
F0/F1/F2 51 (71) 25 (35) 
F3/F4 21 (29) 47 (65) <0.0
Score activity
0/1 53 (62) 33 (38) 
2/3 16 (31) 37 (69) 
IQR, interquartile range; AST, aspartate aminotransferase; ALT, alanine aminotransfera
a Results are expressed as the count (percentage) unless stated otherwise. Statistical s
test, or Student t-test (with a Welch correction of variance when necessary).patients. Genotypes 1 (43.95%), 2 (25.11%), and 4 (28.25%) were
the most common.
As concerns the description of clinical and laboratory aspects of
patients found to be anti-HCV-positive, not much has been done in
Sub-Saharan Africa. In most countries like Cameroon, Nigeria, and
Burkina Faso, previous studies have described the prevalence of
anti-HCV antibodies as well as their genotype distribution in
speciﬁc populations,22,23 most with a small number of patients.24
In the present study population, over 90% of patients were aged
over 40 years. This ﬁnding is consistent with those of previous
studies in Cameroon suggesting a cohort effect with an old,
possibly iatrogenic group exposure, rather than continuous
exposure.23,25 A similar hypothesis of a cohort effect was
postulated in Turkey, Spain, Italy, Japan, and China, where the
risk of HCV infection was higher in the distant past 40–60 years
previously.26 However, although the present study found a low
prevalence in those aged below 40 years, there is no room for
complacency, especially as many of the study patients admitted to
potential risk factors for HCV transmission, notably a history of
surgery, blood transfusion, and scariﬁcation. The latter is still
common practice in this region and should be addressed. This calls
for thorough reinforcement of the World Health Organization
2014 guidelines on the health care-associated transmission of
infections and blood safety.7 Although potential risk factors for
HCV transmission in the present study were consistent with those
of previous studies in Cameroon, they contrast greatly with those
of middle and high income countries where most HCV infections
occur among injection drug users.7,27
Comorbidity was prominent in the study population, including
diabetes and hypertension. This could be simply because the study
population was made up mostly of people above the age of
40 years. The presence of numerous comorbidities in this
population is a call for concern when treatment becomes more
available, because these may be factors associated with a poor
response to antiviral drugs or adherence issues related to a high pill
burden. Another problem is that of alcohol use: one in four usededian agea
lue 57 years >57 years p-Value Total (%)
17 64 (24) 73 (29) 0.19 137 (26)
 21 (47) 24 (53) 0.50 45 (9)
1 2 (29) 5 (71) 0.27 7 (1)
 8 (18) 37 (82) <0.0001 45 (9)
9 15 (34) 29 (66) 0.016 44 (8)
4 11 (19) 46 (81) <0.0001 57 (11)
001 6 (29) 15 (71) 0.032 21 (4)
001 12.9 (11.5–14.1) 12.6 (10.9–13.6) 0.03 12.7 (11.3–13.9)
043 199 (150–250) 165 (114–223) 0.0001 180 (130–230)
2 38 (26–63) 55 (32–88) <0.0001 45 (29–77)
1 40 (27–65) 50 (30–77) 0.01 43 (28–71)
7 8 (4.4–12.3) 7.9 (4.2–13.5) 0.89 8 (4.4–13)
6 38 (32–43) 35.7 (28.4–41) 0.035 36 (30.7–42.3)
1 4.1 (1.4–15.5) 5.6 (2.8–23.3) 0.13 5.4 (1.7–17.4)
1 3.5 (1.6–28.2) 19.8 (6.1–36.7) 0.057 13.1 (2.9–31.2)
2 7.0 (3.6–19.0) 10.3 (4.7–15.7) 0.49 7.3 (4.1–18.3)
58 (62) 18 (35) 76 (53)
001 35 (38) 33 (65) 0.002 68 (47)
61 (71) 25 (29) 86 (55)
30 (59) 23 (41) 51 (45)
se.
igniﬁcance was assessed by Chi-square test, Fisher’s exact test, Wilcoxon rank sum
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programs for alcohol-related harm reduction, even before antiviral
treatment becomes easily accessible in this setting.7,14
Clinically, HCV often remains asymptomatic and unrecognized
until complications of the virus arise. When symptoms are present,
they are non-speciﬁc and can be extra-hepatic in about three-
quarters of patients with mild hepatic disease in some series.28 In
the present study, about a tenth of patients presented with chronic
joint pain presumed to be an extra-hepatic manifestation. On
clinical examination, about a third of the study population had
hepatomegaly, unlike a study performed in London in 1993 in
which it was found that about one in two patients presented with
hepatomegaly.29 This suggests that care-givers should thoroughly
investigate any patient who presents with hepatomegaly, espe-
cially in the setting of the present study where routine checkup is
not common practice, and an association with splenomegaly and
ankle edema could be indicative of decompensated liver cirrhosis,
as over 10% of the study population presented with cirrhosis.
Having in mind the implementation and scale-up of targeted
anti-HCV treatment, systematic genotyping following quantitative
HCV RNA results is important if the epidemiology of the virus is to
be fully understood. Although the present ﬁndings are in
conformity with the large heterogeneity in HCV genotype
distribution in Cameroon, predominantly 1, 2, and 4,22,23 a
particularity of this study population is the presence of genotype
5, dual genotypes, and multiple subtypes. Unlike other studies
which have described genotype 4 to be predominant in 50–75% of
patients with HCV in Cameroon22,23 and in all patients in a small
study in neighboring Gabon,15 genotype 1 was found to be most
common. The presence of numerous subtypes in the study
population could be explained by the study being hospital-based,
where the patients have diverse regions of origin, but does not fully
explain why genotype 1 was predominantly found. However, the
ﬁnding of diverse genotypes and subtypes iterates the fact that
scaling up treatment should be patient-speciﬁc, as the cost of each
treatment might be affected by the viral response, which depends
on the particular genotype.
In the assessment of the degree of liver ﬁbrosis in HCV infection,
liver biopsy is the gold standard.7 Not only is it an invasive
procedure with associated risks, but it also requires highly trained
and skilled histological interpretation,7 which is not readily
available in the present study setting. Although the FibroTest
has been validated as a proxy for liver biopsy, it is still not locally
available, thus limiting the ability to thoroughly evaluate those
patients who are positive for HCV. However, in resource-limited
settings, based on a systematic review of performance and taking
cost into consideration, the AST-to-platelet ratio index (APRI) and
FIB4 test are considered more suitable,7 a recommendation that
must be included in our local guidelines. This therefore means that
setting up an anti-HCV treatment program in the present study
setting should not only address drug availability and accessibility,
but should also consider paraclinical workup.
A large population of 524 anti-HCV-positive patients is
described herein. Nonetheless, this study had some limitations.
It was hospital-based, from clinical ﬁles, which most of the time are
not subject to uniform recording (systematic differences in the way
information is collected by each practitioner), thus there is the
possibility of missing or limited information. Moreover there were
no denominators from which to calculate any measure of the
burden of the disease in this study. The high cost of HCV RNA
quantiﬁcation and FibroTest and the lack of local availability of
such tests limited the complete evaluation of patients. Being a
single-center study, this may represent only a partial insight into
the reality of HCV infection in the hospital setting in Cameroon.
However, the results permit us to have a baseline clinical andbiological proﬁle of the patients, which is an important template
required to set up extensive and targeted anti-HCV treatment.
In conclusion, a good number of anti-HCV-positive patients
attending DGH have no presenting complaints; as such, many
patients are diagnosed fortuitously, some of whom already have
complications including cirrhosis and HCC. Genotype 1 was the
most commonly found in this hospital setting. There is an urgent
need to put in place programs to increase awareness and diagnosis
of HCV infection and to develop extensive and targeted anti-HCV
treatment guidelines to improve the management of these patients
in Cameroon.
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